drugset / Trial / NCT00060710
CP-461 in the Treatment of Patients With Advanced Melanoma
Phase 2
Terminated
35 enrolled
Astellas Pharma Inc
Cell Pathways · collabOSI Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of CP-461 given twice daily orally in patients with advanced or metastatic malignant melanoma and to evaluate the safety profile of CP-461 in this patient population.
Timeline
- Start
- 2003-01
- Primary completion
- —
- Completion
- 2004-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CP-461 | Small molecule | — | Oral |